Charles River Laboratories Acquires MPI Research

Feb 13, 2018
By Pharmaceutical Technology Editors
Volume 13, Issue 3

Charles River Laboratories International announced on Feb. 13, 2018 that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, expanding its early-stage contract research offerings for the biopharmaceutical and medical device markets.

MPI, a Mattawan, MI-based non-clinical contract research organization (CRO), provides comprehensive testing services from its one-million-sq.-ft. facility. The acquisition will add ototoxicity and abuse liability capabilities to Charles River’s services, and will expand

existing capabilities in general and specialty toxicology, including ophthalmology, juvenile toxicity, molecular biology, and surgery, as well as medical device testing, Charles River reports.

In the announcement, Charles River reported strategic benefits of expanding its biotechnology client base, adding infrastructure for safety assessment, and generating revenue growth.

The transaction is expected to close in the second quarter of 2018, according to a Charles River press statement.

Source: Charles River Laboratories

 

native1_300x100
lorem ipsum